Table 4

Characteristics of patients in the independent test set 2

Sample ID

Age (years)

Sex

Bacterial isolation

Antibiotherapy before blood collection

Underlying diseases

Survival


Other sepsis (n = 7)

I027*

64

Female

E. coli

Fortum, ceftriaxone

UGIB

Non-survivor

I028

81

Female

Corynebacterium spp.

Ceftriaxone, fortum, clindamycin

T2D

Survivor

I029

74

Female

S. aureus

Fortum, ceftriaxone, tazocin

Asthma, emphysema, ARF

Survivor

I031*

48

Male

Enterococcus spp.

Fortum

Urinary tract infection

Survivor

I032*

54

Female

E. faecium

Fortum, tazocin

T2D, respiratory failure

Non-survivor

I033*

63

Female

E. coli

Tazocin, ceftriaxone, fortum

T2D, ovarian cancer

Survivor

I034*

43

Male

A. hydrophila

Tazocin

-

Survivor

Septicemic melioidosis (n = 8)

M031*

49

Male

B. pseudomallei

Fortum, bactrim, tazocin

T2D

Non-survivor

M032*

54

Male

B. pseudomallei

Fortum, doxycycline, sulperazone

T2D

Non-survivor

M033*

44

Male

B. pseudomallei

Fortum, sulperazone, bactrim, ciprofloxacin

T2D

Survivor

M034*

40

Female

B. pseudomallei

Fortum, bactrim, ceftazidime, ceftriaxone

T2D

Survivor

M035*

56

Male

B. pseudomallei

Ceftriaxone, ceftazidime, fortum

COPD, T2D

Non-survivor

M036*

41

Female

B. pseudomallei

Ceftriaxone, ceftazidime

T2D

Non-survivor

M037*

42

Female

B. pseudomallei

Bactrim, fortum, cloxacillin

T2D

Survivor

M038*

49

Female

B. pseudomallei

Ceftriaxone, fortum, ceftazidime, levofloxacin

-

Non-survivor


*Community-acquired septicemia; hospital-acquired septicemia. Positive by two sets of blood cultures. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; T2D, type 2 diabetes; UGIB, upper gastrointestinal bleeding.

Pankla et al. Genome Biology 2009 10:R127   doi:10.1186/gb-2009-10-11-r127

Open Data